| Executive Board | Dario Riccardo Valenzano, Birgit Oechsner, Wilfried Briest [1] |
|---|---|
| Faculty | Life Sciences |
| Staff | 370 people |
| Budget | 37 million Euros (2023) |
| Address | Beutenbergstraße 11 D-07745 Jena, Germany |
| Location | , , Germany |
| Website | www |
The Leibniz Institute on Aging - Fritz-Lipmann-Institute (FLI) is a non-university research institution located at the Beutenberg Campus in Jena and is involved in basic biomedical research in the field of life science. the institute is a member of the Leibniz Association. The FLI is run in private legal form as a registered association. When it was founded, the FLI was the first national research institute to devote itself to basic biomedical research in the field of ageing research / gerontology on a broad scale. [2]
History of the institute
editThe first predecessor of the institute was the "Schott-Zeiss Institute for Microbiology", founded in 1944, from which the "Institute for Microbiology and Experimental Therapy" emerged in 1953. In 1970, the institute was renamed the Central Institute for Microbiology and Experimental Therapy (ZIMET) of the Academy of Sciences of the GDR.
After reunification, the former ZIMET was essentially divided into two institutes in 1991: the Hans Knöll Institute (HKI) and the Institute of Molecular Biotechnology (IMB). The IMB focused on research in the field of evolutionary biotechnology and genome sciences and, from January 1992, was one of the research institutions jointly funded by the federal and state governments in the then "Blue List", now the Leibniz Association.
Following an evaluation of the Institute, the German Council of Science and Humanities proposed a new research concept for the IMB in 1999. As a result, Prof. Peter Herrlich was appointed as the new director of the IMB in 2003. In 2005, the institute was renamed the "Leibniz Institute on Aging - Fritz Lipmann Institute" (FLI) to reflect its new scientific orientation.
The institute is named after the German-American biochemist Fritz Lipmann (1899-1986), who was awarded the Nobel Prize for Medicine in 1953 for his discovery of Coenzyme A as an important intermediate in lipid metabolism.
Research and development
editThe aim of biomedical ageing research at the FLI is to decipher the genetic, epigenetic and molecular processes that underlie age-related changes. Ageing is a highly complex process that is influenced by genetic and external factors. Research at the FLI aims to create a scientific basis for the development of novel therapeutic approaches that help to extend the health span - i.e. the time during which people age healthily.
Web links
edit
* Leibniz-Institute on Aging - Collection of images, videos and audio files
Individual references
editAnnual report 2019-2020 [1]